GOP vs. Trump on Cannabis: House Defies Rescheduling 2026

American cannabis politics has officially entered the twilight zone.

On April 23, 2026, President Trump's Department of Justice issued a final order moving state-licensed medical marijuana to Schedule III of the Controlled Substances Act — the most significant federal cannabis reform in modern history. White House Press Secretary Karoline Leavitt defended the move as "overwhelmingly popular with the vast majority of Americans" and framed it as common-sense policy for patients who need cannabis for medical treatment.

One week later, on April 30, a GOP-led House appropriations subcommittee voted to include language in a spending bill that would block the DOJ from using funds to implement broader rescheduling — directly contradicting the president's own executive order. The same party, in the same Congress, working at cross-purposes on one of the most popular policy reforms in America.

Welcome to the Republican Party's cannabis civil war.

The Timeline of Contradiction

To appreciate just how unusual this situation is, you need to understand the sequence of events.

On December 18, 2025, President Trump signed an executive order directing the DOJ and DEA to expedite marijuana rescheduling, citing the need to increase medical marijuana research and align federal policy with the medical consensus on cannabis. The order was consistent with Trump's campaign rhetoric — he had repeatedly expressed support for medical marijuana and criticized the federal classification of cannabis as a Schedule I substance alongside heroin and LSD.

On April 23, 2026, the DOJ acted on that order by issuing a final rule placing FDA-approved marijuana products and state-licensed medical marijuana in Schedule III. The DEA followed up by scheduling an expedited administrative hearing beginning June 29 to consider broader rescheduling of all marijuana — including recreational products.

Then, on April 30, the House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies advanced a spending bill containing language that would prohibit the DOJ from using any funds to reschedule marijuana beyond the narrow categories already addressed. If this language makes it into a final appropriations package that the president signs, it could freeze the broader rescheduling process in place.

The contradiction is breathtaking. The executive branch is moving forward with rescheduling. The legislative branch — controlled by the president's own party — is trying to stop it. And the subcommittee members voting to block the reform are doing so with full knowledge that the president has publicly endorsed the policy they're trying to kill.

Why Some Republicans Want to Block Rescheduling

The motivations behind the congressional opposition are varied, and understanding them is essential to making sense of this apparent paradox.

The most substantive objection is procedural. Some Republican lawmakers argue that rescheduling marijuana through executive action, rather than through legislation, sets a dangerous precedent for executive overreach. They contend that the Controlled Substances Act gives Congress authority over drug scheduling decisions, and that the DOJ's unilateral action circumvents the legislative process. This argument has appeal across ideological lines — concerns about executive power aren't limited to cannabis policy.

Then there's the law enforcement constituency. Organizations like the National Sheriffs' Association and various police unions remain opposed to any relaxation of federal marijuana laws, and they exercise significant influence over Republican lawmakers, particularly those from rural and suburban districts where law enforcement endorsements carry political weight.

Social conservative groups, including organizations affiliated with the evangelical movement, have also lobbied against rescheduling. Their opposition tends to be rooted in concerns about drug use normalization, youth access, and the moral implications of federal endorsement of marijuana — concerns that resonate with a shrinking but still vocal segment of the Republican coalition.

Finally, there's the pharmaceutical industry. Moving marijuana to Schedule III creates a pathway for cannabis-based medicines to compete with existing pharmaceutical products for pain, anxiety, insomnia, and other conditions. Pharmaceutical companies and their lobbyists have not been publicly outspoken against rescheduling, but their influence on the appropriations process is well-documented.

The Political Math Doesn't Add Up

What makes the congressional blockade so remarkable is that it flies in the face of public opinion — including Republican public opinion. Recent polling shows that 70 percent of Americans support marijuana legalization, with support among Republican voters consistently above 50 percent and climbing. Even among self-described conservative Republicans, support for medical marijuana exceeds 70 percent.

The disconnect between Republican voters and Republican legislators on cannabis is one of the widest gaps between public opinion and legislative action on any major policy issue. It's a gap that the White House has noticed and attempted to exploit. By framing rescheduling as a populist, pro-patient reform, the Trump administration has positioned congressional opponents as out-of-touch with their own base — a politically uncomfortable place for any lawmaker to be.

The irony is particularly acute for appropriations committee members, who are supposed to be among the most pragmatic members of Congress. The committee process is where governing happens — where abstract policy positions are translated into funding decisions that affect real people and real agencies. Blocking rescheduling through the appropriations process is a blunt instrument that ignores the nuance of the issue and creates conflict with the president for no clear political benefit.

Historical Precedent: This Has Been Tried Before

The current attempt to block rescheduling through appropriations isn't the first — and past efforts have failed. In September 2025, the House Appropriations Committee approved a similar provision barring DOJ funds from being used for rescheduling. But when the final bipartisan FY2026 spending deal was negotiated, the blocking language was stripped out. The bill passed the House 397-28 and the Senate 82-15 in January 2026, with the anti-rescheduling amendment defeated by a wide margin.

That history suggests that the current blocking effort faces an uphill battle. Appropriations riders that are controversial enough to threaten broader spending deals tend to get dropped during the conference committee process, where negotiators from both chambers prioritize must-pass spending provisions over policy riders that lack bipartisan support.

But the cannabis industry isn't taking anything for granted. The fact that the blocking language keeps reappearing — even after being rejected multiple times — signals that its proponents are persistent and that the institutional resistance to marijuana reform within Congress remains significant.

What the Rescheduling Fight Really Means

Beyond the procedural wrangling, the GOP's internal cannabis fight is a microcosm of a broader identity crisis within the party. The Trump-era Republican Party has embraced populist positions on a range of issues — criminal justice reform, skepticism of pharmaceutical companies, support for individual liberty and states' rights. Marijuana reform fits naturally within that framework, which is why Trump has been willing to champion it.

But the party's legislative apparatus is still dominated by members whose instincts were formed in the Reagan and Bush eras, when anti-drug messaging was a core Republican brand identity. Changing the policy is one thing; changing the institutional culture that has resisted cannabis reform for decades is something else entirely.

The June 29 DEA hearing on broader rescheduling will be the next major flashpoint. If the hearing produces a recommendation to reschedule all marijuana — including recreational products — the congressional fight will intensify dramatically. And if the appropriations blocking language makes it into a final spending package, the president will face a choice between signing a bill that contradicts his own executive order or vetoing legislation that funds the federal government.

Neither option is comfortable, which is why the most likely outcome is a repeat of January 2026 — the blocking language gets dropped during negotiations, the president's rescheduling agenda moves forward, and the congressional opponents regroup for the next fight. But in Washington, nothing is certain until the ink is dry.

The Bottom Line for Cannabis

For the cannabis industry and its consumers, the GOP's internal fight over rescheduling is both encouraging and frustrating. Encouraging because the trend line is unmistakable — federal cannabis reform is happening, with bipartisan support and presidential backing. Frustrating because the process is slow, contested, and subject to the kind of procedural gamesmanship that characterizes so much of congressional action.

The DEA's hearing in June will be the most important moment for cannabis policy in 2026, and the appropriations subcommittee's blocking vote is a reminder that not everyone in Washington is ready to let that hearing proceed without a fight. But the political dynamics favor reform. Public opinion favors reform. The president favors reform. And the economic evidence from 24 legal states overwhelmingly favors reform.

The question for congressional Republicans who continue to resist isn't whether cannabis reform is coming — it's whether they want to be on the right side of it when it arrives.

For the constitutional separation-of-powers angle and what the rescheduling fight reveals about GOP-Trump tensions, see our follow-up: GOP vs. Trump: The Fight Over Cannabis Rescheduling Powers.

Find a verified shop near you in Budpedia's cannabis dispensary directory.